Treatment for Preventing Immunological Complications using Drug-Free Carriers

Barenholz Yechezkel, HUJI, School of Medicine - IMRIC, Biochemistry and Molecular Biology



Drug Allergy, Drug Delivery, Nano-pharmaceuticals

Development Stage

TRL4, Successfully tested in large animals

Patent Status

US and Europe patent


Intravenous injection of some liposomal drugs, diagnostic agents, micelles and other lipid-based nanoparticles cause hypersensitivity reactions in up to 45% of patients



  • Intravenous infusion of certain drugs and diagnostic agents that contain particles in the range
    10-9-10-6m (particulate medicines PCM) produce pseudo-allergic reactions that appear to be similar to those caused by pollen or foods, but in fact differ from those reactions.
  • PCM reactions appear to be initiated by the complement system (C) of the immune system.
  • Liposomes, micelles, and other particulate drug carriers which do not carry C inhibitors on their surfaces activate these hypersensitive reactions.

Our Innovation

Treatment with a placebo, drug-free carrier, prior to administration of particulate medicines to prevent allergic reactions to the medicines


Key Features

  • Technology specifically inhibits PCM-triggered C3a/C5a receptor-mediated complement activation-related pseudoallergy (CARPA) reactions
  • Toxicology tests for this technology are very simple

The Opportunity

Opportunity to incorporate new technology with minimal regulatory process


Researcher Information            biochemistry.huji.ac.il/faculty_barenholz.asp, research.ekmd.huji.ac.il/researchers.asp?id=166, nanoscience.huji.ac.il/researchers/barenholz.htm



Patent Status

Granted US 9,078,812; Europe 2231190

Contact for more information:

Shani Bullock
VP, Business Development, Healthcare
Contact ME: